David Livingston, MD, of Dana-Farber, Wins Major Cancer Research Award

Article ID: 672018

Released: 28-Mar-2017 5:00 PM EDT

Source Newsroom: Dana-Farber Cancer Institute

  • Credit: Dana-Farber Cancer Institute

    David Livingston, MD

March 28, 2017

Contact: Ellen Berlin 617-632-4090, ellen_berlin@dfci.harvard.edu

David Livingston, MD, of Dana-Farber, wins major cancer research award

Newswise — BOSTON — David M. Livingston, MD, of Dana-Farber Cancer Institute, has won a major award for discoveries in cancer research from the American Association for Cancer Research (AACR).

Livingston, a cancer biologist, will receive the Pezcoller Foundation-AACR International Award and deliver a lecture at the AACR Annual Meeting on April 2, 2017 at the Washington Convention Center in Washington, DC. The award was established in 2007 to recognize a scientist who has made major scientific discoveries in basic cancer research, or who has made significant contributions to translational cancer research; who continues to be active in cancer research, and has a record of recent and noteworthy publications; and whose ongoing work holds promise for substantive contributions to progress in the field of cancer.

Livingston is the Emil Frei Professor of Genetics & Medicine at Harvard Medical School, and is the deputy director of the Dana-Farber/Harvard Cancer Center.

He is a renowned expert on the molecular origins of breast and ovarian cancer, focusing on genes that regulate cell growth, including the tumor suppressor genes Rb, p300/CBP, BRCA1 and BRCA2. His work has been the cornerstone of many studies of cancer susceptibility linked to BRCA function and mutations. By understanding the tumor suppressive properties of BRCA1 and BRCA2, Livingston has paved the way for studying novel approaches to breast and ovarian cancer prevention.

The title of Livingston’s award lecture is, “BRCA1, other Fanconi Gene, and Swi/SNF function Co-sustain Mammary Epithelial Differentiation through DNA Damage Repair.”

About Dana-Farber Cancer InstituteFrom achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report’s Best Hospitals for both adult and pediatric cancer care.

Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women’s Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston’s Longwood Medical Area.

Dana-Farber is dedicated to a unique, 50/50 balance between cancer research and care, and much of the Institute’s work is dedicated to translating the results of its discovery into new treatments for patients locally and around the world.

# # #


Comment/Share





Chat now!